Why Is EDGEWISE THERAPEUTIC (EWTX) Stock Down Today?

EWTX stock is down 6.98% at $43.20 as of the close of the session. The decline follows a report of disappointing second-quarter earnings and a series of recent insider sales. Despite a raised price target from JPMorgan, the stock is trading near its 52-week low amid ongoing pressure from bearish analysts and weak fundamental performance.

What Happened

Edgewise Therapeutics reported Q2 earnings per share of $(0.53), missing the estimated $(0.47) loss. The company remains unprofitable with a trailing twelve-month EPS of -1.85. JPMorgan raised its price target for EWTX to $60 from $53, but the move failed to offset broader skepticism. Goldman Sachs also raised its price target to $36 while maintaining a neutral stance. Meanwhile, Evercore ISI Group and Guggenheim raised their price targets to $55 and $51 respectively, and Oppenheimer initiated coverage with an outperform rating and a $51 price target. Despite these analyst actions, the stock fell sharply during the session, closing near its intraday low.

Three top executives, Kevin Koch, Joanne M. Donovan, and Alan J. Russell, sold shares on August 12, 2026. Over the past 90 days, insiders have sold a total of $9.8 million worth of shares with no insider purchases recorded.

What The Data Shows

The stock opened at $46.63 and reached a high of $46.64 shortly after the market opened. It declined steadily throughout the session, hitting a low of $43.20 at 3:40 PM ET. Trading volume of 0.3 million shares is 0.2 times the 3-month daily average. The stock closed near its 52-week low, having printed 41 fresh 52-week lows on August 20, 2026. The 30-day average sentiment score is 59/100, while the 7-day average is 68/100, indicating a recent improvement in market sentiment.

What To Watch

The stock is currently unprofitable with a market cap of $4.8 billion. Investors should monitor the company’s next earnings report if scheduled, as well as any further analyst coverage or insider activity.